<DOC>
	<DOCNO>NCT02862704</DOCNO>
	<brief_summary>The purpose study collect data safety potential effectiveness intra-tumor injection MG7-CART cell ultrasound guidance patient liver metastasis express MG7 positively .</brief_summary>
	<brief_title>A Study MG7 Redirected Autologous T Cells Advanced MG7 Positive Liver Metastases ( MG7-CART )</brief_title>
	<detailed_description>Designer T cell prepare PBMC patient leukapheresis , activate re-engineered express chimeric antigen receptor ( CARs ) specific MG7 , glycosylated protein CEA . Cells expanded culture return participant intra-tumor injection dose ( 1-6 ) ×108 CAR positive T cell . The cell perfusion process would last 1min 2min . The dose 1.5 grams/m2 cyclophosphamide give two day CART cell infusion .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>MG7 expression positive histologically confirm ; Aged 18 69 ; Persistent cancer least one prior standard care chemotherapy , willing surgery suitable surgery patient ; Tumor big surgical resection ; Life expectancy great 4 month ; Satisfactory organ bone marrow function define follow : ( 1 ) creatinine &lt; 1.5mg/dl ; ( 2 ) cardiac ejection fraction &gt; 55 % ; ( 3 ) hemoglobin &gt; 9g/dl , bilirubin 2.0×the institution normal upper limit ; Without bleed disorder coagulation disorder ; Dont allergy Radiocontrast agent ; Birth control ; Adequate venous access apheresis , contraindication leukapheresis ; Voluntary inform consent give . Pregnant lactating woman ; Concurrent use systemic steroid . Recent current use inhale steroid exclusionary ; Patients situation : ( 1 ) 30 day apheresis still period antitumor drug observation ; ( 2 ) patient dont recuperate earlier acute adverse influence bring treatment accept ; Four week recruit accept radiation therapy ; Previously treatment gene therapy product ; Feasibility assessment screen demonstrates &lt; 30 % transduction target lymphocytes , insufficient expansion ( &lt; 5fold ) response CD3/CD28 costimulation ; Any serious , uncontrolled disease ( include , limit , unstable angina pectoris , congestive heart failure , grade III IV cardiac disease , serious arrhythmia , liver kidney disorder metabolic disease , CNS diseases ) ; Patient severe acute hypersensitive reaction ; Taking part clinical trial ; Study leader considers suitable tiral .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>